News

BioDelivery Sciences has received a $2.5 million milestone payment for completion of the clinical trial work supporting the dossier and expects to receive an additional milestone payment on

Breze Pads (benzoyl peroxide 4.75% and 7.75%) complement the current ATS portfolio which also includes Zytopic (triamcinolone acetonide, 0.1%), Coraz (hydrocortisone lotion USP, 2%), and the Xyralid (lidocaine

Pursuant to the special protocol assessment, the Phase III trial will be a randomized, double-blind, placebo-controlled trial of CB7630 plus prednisone in patients with metastatic castration-resistant prostate cancer

This orphan designation qualifies the company and it’s Neo-Bladder Augment for European Medicines Agency (EMEA) regulatory incentives, including eligibility for protocol assistance and possible exemptions or reductions of

The first compound that Epistem will assess is Exponential Biotherapies’s (EBI’s) lead candidate drug, EA-230, which is a small peptide immunoregulator that has shown the potential to treat

Solumed employs approximately 25 people and will remain in Quebec as a separate subsidiary of 3M Canada. Solumed brings a chlorhexidine gluconate and alcohol-based line of products to

In the study’s intent-to-treat group at 3 months, more than four times as many positive responses to treatment were documented in subjects randomized to the NX-1207 therapeutic dose

The HRP Initiative is a pre-competitive industry collaboration that is focused on discovering and developing novel blood tests and imaging methods to find individuals with high-risk plaque disease

Recently Supratek has also reached an agreement with the FDA for the design of SP1049C pivotal phase III study protocol under the special protocol assessment process. Recently Supratek